Featured Post from Augusta University

One year later, what comes next for Ukraine?

Feb 24, 2023

4 min

Craig Albert, PhD

The war between Ukraine and Russia has raged for a year, with both sides gaining and losing ground while casualties mount and no clear prospects for peace seem to emerge.



On the anniversary of this invasion, there are still many questions to be asked, and Augusta University Professor Craig Albert, PhD, is ready to provide answers about what's happening and what we can expect next.


How surprising is it that the Ukraine-Russian war is still ongoing?


“I think for Russia, it’s a huge surprise, and I think maybe for the rest of the world, it’s a bit of a surprise as well. What people often forget is that Ukraine has been fighting and training for 10 years. So Moscow was going on the understanding that the way and the ease in which they went into those parts of Ukraine in 2014, that they would have the same amount of ease this time. They didn’t calculate properly or they misperceived that Ukraine soldiers have been fighting them and rotating in and out of the east for 10 years and had much more experience and were prepared for this.”


How does the anniversary play a role in the war?


“Everyone knew Putin was going to increase the attacks leading up to the year anniversary. Both sides have been expecting a new counter offensive against each other coming for the spring. What we should note from this is that a couple of times over the past couple of weeks, the Russian death toll has been over 1,000 per day. Think of that as the United States lost something like 5,000 in Iraq, the entire 17-18 years the US was there. So that’s something we need to take into account. They are increasing their attacks but they’re meeting massive resistance and some are calling it a meat grinder, where the Russian side is just throwing troops into it and they are just being mowed down.”


While Ukraine has been preparing for some time, was their resolve still unexpected?


“I think their resolve is based upon the fact they’re getting so many munitions from the west. I think their resolve and morality would be much worse if they weren’t getting the type of equipment, the type of war material that the west is providing them. If it wasn’t for the west helping them, I think we’d be talking a much different scenario. If Russia is successful in the war and how they define success, and they occupy all of Ukraine, then that’s a likely scenario. If Ukraine continues a war of attrition with Moscow, the war of numbers suggest that Moscow is going to win. You’re looking at Russia ultimately winning just because of the law of numbers."




What do you make of President Biden’s visit to Ukraine?


“It’s a huge symbolic victory. I did not expect President Biden to visit Ukraine at all. I thought that was gutsy. I think both sides of the aisle thought that was pretty gutsy. That’s a pretty scary situation and presidents generally don’t visit a war-torn country, even when the United States is at war. I think it was a show of strength, a show of unity, maybe even a show of what’s to come with EU ascension or NATO ascension for President Biden to be on the ground in Kiev.”


How long do you see this continuing?


“It depends on how far Russia is willing to go. Russia isn’t fighting the war if it fought the United States. Russia has the capability to completely bombard and send in massive numbers of untrained soldiers by the hundreds and thousands and just overwhelm Ukraine. I think why they’re not doing that is that they still want to control and have a friendly Ukrainian population once they completely have all the territory of Ukraine. I think that’s Putin’s goal and that’s why he hasn’t done that so far. I think we’re looking at least another year. These types of huge wars, and this is a major, major war, it has the propensity to pull in outside parties. And when you’re talking about NATO being right there, we could be talking about something much bigger if this war doesn’t cease soon.”




Albert can explain what could happen next in Ukraine, as there are several possible scenarios and outcomes in the long and short term of this war. And if you’re a journalist looking to know more about what lies ahead as the war between Ukraine and Russia continues and how it may impact the United States, then let us help with your questions and coverage.


Albert is director of the Master of Arts in Intelligence and Security Studies at Augusta University. He is a leading expert on war, terrorism and American politics. This is an important national and international issue. Albert is available to speak with media – simply click on his name to arrange an interview today.

Connect with:
Craig Albert, PhD

Craig Albert, PhD

Graduate Director, PhD in Intelligence, Defense, and Cybersecurity Policy and Master of Arts in Intelligence and Security Studies

Dr. Craig Albert focuses on propaganda, information warfare, national security studies, cyberconflict, and political thought.

Political PhilosophyEthnic ConflictInfluence OperationsCybersecurity Policy & StrategyInternational Security Studies

You might also like...

Check out some other posts from Augusta University

3 min

MCG scientists investigate arthritis drug’s impact on Alzheimer’s disease

According to the Alzheimer’s Association, more than 7 million Americans are living with Alzheimer’s disease, and one in nine of those people is 65 or older. Although that number is expected to grow, researchers at the Medical College of Georgia at Augusta University are making progress on studies that could turn into life-saving treatments. Qin Wang, MD, PhD, professor in the Department of Neuroscience and Regenerative Medicine at MCG and Georgia Research Alliance Eminent Scholar in neuropharmacology, recently published a study titled “The PKCι‑β‑arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease,” in Molecular Degeneration, a leading journal in neurodegeneration. In the study, Wang and her team explored how certain proteins and enzymes interact in the brains of Alzheimer’s patients. Key players include the SORL1 gene, the PKCι enzyme and proteins SORLA, β‑arrestin2 and amyloid. SORL1 encodes SORLA, which helps regulate amyloid. Amyloid can form plaque in the brain, contributing to Alzheimer’s. People with the disease often have lower SORLA levels, which amplifies plaque production. “The goal is to increase SORLA levels in patients with AD. If we can boost it up, that would be great,” Wang said. “But if you want to know how to boost it up, you have to know how it is degraded, so that’s what our work is about – we’re trying to understand how its stability is regulated.” Wang’s research team found that PKCι can add a phosphate group to SORLA, which helps SORLA interact with β‑arrestin2. The PKCι‑β‑arrestin2 axis leads to SORLA degradation, reducing its levels and allowing amyloid plaques to grow unchecked, thereby worsening the disease condition. They discovered this by using biochemical methods and a mass spectrometer managed by Wenbo Zhi, PhD, at the Proteomics and Mass Spectrometry core lab at AU. “We conducted biochemical studies and found that SORLA can be phosphorylated. We identified the phosphorylation site and the interacting enzymes,” Wang explained. “Using the mass spectrometer with PKCι, we saw increased phosphorylation of SORLA at certain sites. Preventing that could stop SORLA degradation.” That’s where a rheumatoid arthritis drug called auranofin comes into play. “While it is an arthritis drug, it can also inhibit the PKCι enzyme,” Wang explained. The team conducted tests using Alzheimer’s mouse models and human iPS cells developed into neurons. For the mouse models, they treated the mice with auranofin for eight weeks, resulting in decreased amyloid levels, reduced neuroinflammation and improved cognitive function. Similar results were seen in human cells with increased SORLA levels and decreased amyloid levels. “A good thing about this is, because this is an FDA-approved drug, it’s ready to be tested in Alzheimer’s patients,” Wang said. “People often worry about drug safety because of long-term use in chronic diseases like Alzheimer’s, but, in this case, existing safety data for chronic use gives a good starting point for testing in Alzheimer’s patients. “I hope a drug company can pick that up for a trial with Alzheimer’s patients because we are trying to translate our bench work all the way to the bedside for treatment,” she continued. The study wraps up a five-year National Institute on Aging grant, a collaborative effort between Wang’s lab and the Kai Jiao, MD, PhD, lab in AU’s Center of Biotechnology and Genomic Medicine. Wang’s team is also working on other grant-funded Alzheimer’s-related projects and hopes to continue making advancements toward finding a cure for this debilitating disease. “All of our projects share the goal of finding a better treatment,” Wang said. “Related to this project in particular, we want to know how the SORLA protein works in different types of brain cells, given the brain’s complexity. Then we can determine how to specifically target that protein to develop more effective therapies.” Qin Wang, MD, PhD, researches the neuropharmacology and signaling mechanisms underlying neurological and psychiatric disorders. If you're interested in learning more about her work or booking an interview,  simply click on her icon now to arrange a time to talk.

2 min

Experts in the Media: CBD may help treat and reduce inflammation in Alzheimer's disease

In a recent Medical News Today article, Corrie Pelc reported on a study led by Babak Baban, PhD, in which inhaled CBD (cannabidiol) was tested in a mouse model of Alzheimer’s disease to examine its effects on neuroinflammation. Baban, associate dean for Research with AU's Dental College of Georgia and a professor with appointments in neurology and surgery in the Medical College of Georgia at Augusta University, explained that previous work from his group showed inhaled CBD to be more effective than oral or injected forms for certain neurological conditions, motivating them to explore its potential in Alzheimer’s research. He emphasized that Alzheimer’s is driven by multiple interacting biological processes – not just amyloid plaques – and sees inflammation as a promising new therapeutic target. In the study, inhaled CBD lowered activity in two major immune “alarm” pathways – IDO (indoleamine 2,3-dioxygenase) and cGAS-STING – both implicated in chronic inflammation. By dampening these pathways, CBD reduced levels of inflammatory cytokines and helped restore a more balanced immune environment in the brain. Baban framed this as a shift from symptom treatment to addressing underlying immune dysfunction, and noted that the findings could reorient how Alzheimer’s is approached. At the same time, he stressed that human trials are still needed: his team is preparing translational studies and holds an active Investigational New Drug (IND) application with the FDA for inhaled CBD in neuroinflammatory conditions, with Alzheimer’s disease as a natural next step. Read the full article here: Babak Baban, PhD, is a professor, immunologist and associate dean for research at the Dental College of Georgia at Augusta University where he has served for 13 of his 20 years as a translational and clinical immunologist. View his profile here Looking to know more about this important research or to connect with Babak Baban, PhD? He's available to speak with media – simply click on his icon to arrange an interview today.

3 min

Nursing researcher receives over $500K in prestigious grants

For the first time in nearly 15 years, a faculty member from Augusta University’s College of Nursing has been awarded a grant from the National Institutes of Health. Blake McGee, PhD, has secured an R03 award of $176,331 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to study Medicaid’s expanded role in late postpartum maternal health. But he hasn’t stopped there as McGee is also part of the fifth cohort of Betty Irene Moore Fellows, a prestigious program for nurse leaders and innovators that has awarded CON half a million dollars to support his research project and leadership development. McGee, the prelicensure department chair and an associate professor, is collaborating with colleagues from other Georgia universities on both studies, which are occurring simultaneously. “I began my career as an ER nurse and have always wanted to ask bigger questions about the challenges facing patients and how we might best address them as a society,” said McGee, who was recently selected for publication in Blood Advances, the American Society of Hematology’s journal. “As nursing scientists, we are uniquely poised to ask questions about healthcare policy, specifically from the vantage point of the impact that policy choices have on patients and their health outcomes.” This century, the United States has seen rising maternal mortality rates with alarming racial disparities. Over half of these deaths occur in the postpartum period, with 23% occurring more than six weeks after delivery. Medicaid expansion covers pregnant women in households below 138% of the Federal poverty level through postpartum day 60, which has been associated with decreased mortality and reduced racial disparity in maternal death. At the time of grant submission, pregnancy Medicaid eligibility traditionally lapsed 60 days after delivery, leaving postpartum people vulnerable to disruptions in care. McGee’s work aims to identify changes in maternal health care use and health outcomes 60 days to 1 year after delivery that were associated with state Medicaid expansions (2007–19). The team will examine whether the effects of expansion vary by maternal race or ethnicity and will explore whether patient-reported health care access and quality mediate the relationships between expansion and outcomes. “My hope is that after the study we’ll have a better understanding of how health and health care use change for women in this crucial late postpartum period and how they may differ for people of different backgrounds,” said McGee. “Due to the sample design, findings will reliably inform optimal policy for postpartum coverage duration.” He expects this study to provide preliminary data for a future R01-funded study that directly examines the impact of extending the duration of postpartum Medicaid under the American Rescue Plan. As part of the Betty Irene Moore Fellowship, McGee is one of 15 fellows across the nation in a curriculum co-delivered by the UC Davis School of Nursing and Graduate School of Management. A project coordinator from AU’s School of Public Health will also assist with the fellowship project. McGee hopes to involve graduate research assistants or recent alumni as research associates on the team. Specifically, McGee will be studying the Georgia Pathways to Coverage Program, making him one of the only academic researchers in the nation funded to do so. “As a researcher, it is always a privilege to engage in topics that directly impact the current state of health care, and I’m honored to tackle projects that are so relevant to today’s health policy headlines,” he said. Georgia stands out among other states that are exploring an extension of Medicaid to low-income, working-age adults who demonstrate a monthly commitment of 80 hours to an employment-related activity. By studying the effects of this program, McGee predicts the findings will be highly relevant to anticipating the impact of recent Medicaid changes at the federal level and may indicate differences between Pathways participants and those who might qualify but remain uninsured. This focus could provide data that helps the state target enrollment efforts. The state’s own logic model predicts that the program will reduce hospitalizations, and McGee is eager to determine the program’s success. “Our findings should be helpful to the state to better understand those enrolling, what their experience with increased access to care has been and how their health has improved after receiving coverage,” McGee said.

View all posts
Powered by